Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)

被引：24

作者：

Hu, M. ^{[1
]}

Subbiah, V. ^{[2
]}

Wirth, L. J. ^{[3
]}

Schuler, M. ^{[4
,5
]}

Mansfield, A. S. ^{[6
]}

Brose, M. S. ^{[7
]}

Curigliano, G. ^{[8
,9
,10
]}

Leboulleux, S. ^{[11
]}

Zhu, V. W. ^{[12
]}

Keam, B. ^{[13
]}

Matos, I. ^{[14
]}

Lin, C-C. ^{[15
]}

Adkins, D. ^{[16
]}

Baik, C. S. ^{[17
]}

Lopes, G. ^{[18
]}

Godbert, Y. ^{[19
]}

Sarker, D. ^{[20
]}

Zhang, H. ^{[21
]}

Turner, C. ^{[21
]}

Taylor, M. ^{[22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA

[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA

[4] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany

[5] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany

[6] Mayo Clin, Div Med Oncol, Rochester, MN USA

[7] Univ Penn, Abramson Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA

[8] IRCCS, Dept Oncol, European Inst Oncol, Milan, Italy

[9] IRCCS, Dept Hematooncol, European Inst Oncol, Milan, Italy

[10] Univ Milan, Milan, Italy

[11] Gustave Roussy, Med Nucl & Endocrine Oncol, Villejuif, France

[12] Univ Calif Irvine, Dept Med, Orange, CA 92668 USA

[13] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[14] Vall dHebron Inst Oncol, Early Drug Dev Unit, Barcelona, Spain

[15] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[16] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[17] Univ Washington, Sch Med, Thorac Head & Neck Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA

[18] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[19] Bergonie Inst Canc Ctr, Nucl Med, Bordeaux, France

[20] Kings Coll London, Dept Med Oncol, Guys Hosp, London, England

[21] Blueprint Med Corp, Cambridge, MA USA

[22] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1401

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1913O

引用

页码：S1084 / S1084

页数：1

共 45 条

[41] RIBOCICLIB (RIB) plus LETROZOLE (LET) IN OLDER PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
De Laurentiis, Michelino
Campone, Mario
Alba Conejo, Emilio
Tanner, Minna
Egle, Daniel
Papai, Zsuzsanna
Prat Aparicio, Aleix
Dent, Susan
Warner, Ellen
Ankrah, Nii
Wu, Jiwen
Zhou, Katie
Borstnar, Simona
BREAST, 2019, 48 : S46 - S47
[42] PHASE II TRIAL OF THE AKT INHIBITOR MK-2206 PLUS ERLOTINIB (ERL) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED AFTER PRIOR BENEFIT (RESPONSE OR STABLE DISEASE) FROM ERL: INTERIM RESULTS FROM PHII-108 (NCI 8698), A CALIFORNIA CANCER CONSORTIUM TRIAL
Lara, Primo
Longmate, Jeffrey
Mack, Philip C.
Kelly, Karen
Li, Tianhong
Koczywas, Mariana
Reckamp, Karen
Gandara, David
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S105 - S106
[43] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Abdel-Razeq, H.
Cottu, P. H.
Ring, A.
De laurentiis, M.
Lu, J.
Azim, H. A.
Zamagni, C.
Zhou, K.
Wu, J.
Menon, L.
Martin, M.
ANNALS OF ONCOLOGY, 2018, 29
[44] Ribociclib (RIBO) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Zamagni, C.
Campone, M.
Kudryavcev, I.
Brown-Glaberman, U.
Cottu, P. H.
Ring, A.
Lu, J.
Martin, M.
De laurentiis, M.
Zhou, K.
Wu, J.
Menon, L.
Azim, H. A.
ANNALS OF ONCOLOGY, 2018, 29
[45] Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET plus ), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm plus ) and progression on gefitinib
Wu, Yi-Long
Yang, James Chih-Hsin
Park, Keunchil
Xu, Lianzhe
Bladt, Friedhelm
Johne, Andreas
Li, Peiqi
Zheng, Hongxia
Massimini, Giorgio
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →